| 周正仕,廖小方,郑勤红.Survivin、BRCA1及class Ⅲ β-tubulin在非小细胞肺癌组织中的表达及与紫杉醇耐药的关系[J].肿瘤学杂志,2012,18(11):806-810. |
| Survivin、BRCA1及class Ⅲ β-tubulin在非小细胞肺癌组织中的表达及与紫杉醇耐药的关系 |
| Expression of Survivin，BRCA1 and class Ⅲ β-tubulin in Non-small Cell Lung Cancer and Its Relationship with Resistance to Paclitaxel |
| 投稿时间：2012-01-05 |
| DOI：10.11735/j.issn.1671-170X.2012.11.B002 |
|
 |
| 中文关键词: Survivin BRCA1 class Ⅲ β-tubulin 肺肿瘤 紫杉醇 耐药 |
| 英文关键词:Survivin BRCA1 class Ⅲ β-tubulin lung neoplasms paclitaxel drug resistance |
| 基金项目: |
|
| 摘要点击次数: 1607 |
| 全文下载次数: 850 |
| 中文摘要: |
| 摘 要：［目的］ 探讨Survivin、BRCA1及class Ⅲ β-tubulin蛋白在非小细胞肺癌（NSCLC）中的表达及与紫杉醇耐药的关系。［方法］ 应用免疫组织化学法检测64例NSCLC患者Survivin、BRCA1及class Ⅲ β-tubulin蛋白的表达；给予紫杉醇为基础的化疗方案，分析上述蛋白表达与紫杉醇化疗敏感性的关系。［结果］ Survivin阳性与class Ⅲ β-tubulin阳性患者对紫杉醇方案治疗的有效率（RR）分别低于Survivin阴性患者（27.8% vs 71.4%，P<0.05）与class Ⅲ β-tubulin阴性患者（23.5% vs 73.3%，P<0.01）；而BRCA1阳性患者对紫杉醇方案治疗的RR高于BRCA1阴性患者（60.0% vs 31.0%，P<0.05）。多因素分析表明class Ⅲ β-tubulin是NSCLC紫杉醇治疗无进展生存期（PFS）的独立影响因素（χ2=4.852，P=0.027），分期是与总生存期（OS）相关的独立影响因素（χ2=4.105，P=0.035）。［结论］ NSCLC患者Survivin、class Ⅲ β-tubulin蛋白表达阳性及BRCA1蛋白表达阴性预示对紫杉醇治疗相对不敏感。 |
| 英文摘要: |
| Abstract: ［Purpose］ To investigate the relationship between the expression of Survivin，BRCA1 and class Ⅲ β-tubulin proteins and resistance to paclitaxel in patients with non-small cell lung cancer(NSCLC). ［Methods］ The expressions of Survivin，BRCA1 and class Ⅲ β-tubulin in 64 cases with NSCLC were detected by immunohistochemical method. Patients received paclitaxel-based chemotherapy.The relationship between the expression of 3 kinds of proteins and sensitivity of paclitaxel-chemothrapy was analyzed.［Results］ The response rate(RR) of paclitaxel-based chemotherapy in patients with positive Survivin expression or positive class Ⅲ β-tubulin expression was lower than that in negative Survivin expression patients (27.8% vs 71.4%，P<0.05) or negative class Ⅲ β-tubulin expression patients (23.5% vs 73.3%，P<0.05) .RR in positive BRCA1 expression patients was higher than that in negative BRCA1 expression patients (60.0% vs 31.0%，P<0.05). Multivariate analysis showed that class Ⅲ β-tubulin was independent factor for progression-free survival(χ2=4.852，P=0.027) and stage was independent factor for overall survival(χ2=4.105，P=0.035).［Conclusion］ Positive expressions of Survivin and class Ⅲ β-tubulin and negative BRCA1 expression in NSCLC patients might be associated with resistance to paclitaxel-based chemotherapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |